Recently another long period radio pulsar GPM J1839-10 has been reported,similar to GLEAM-X J162759.5-523504.3.Previously,the energy budget and rotational evolution of long period radio pulsars had been considered.Thi...Recently another long period radio pulsar GPM J1839-10 has been reported,similar to GLEAM-X J162759.5-523504.3.Previously,the energy budget and rotational evolution of long period radio pulsars had been considered.This time,the death line and pulse width for neutron star and white dwarf pulsars are investigated.The pulse width is included as the second criterion for neutron star and white dwarf pulsars.It is found that:(1)PSR J0250+5854 and PSR J0901-4046 etc.should be normal radio pulsars.They have narrow pulse width and they lie near the radio emission death line.(2)The two long period radio pulsars GLEAM-X J162759.5-523504.3 and GPM J1839-10 are unlikely to be normal radio pulsars.Their possible pulse width is relatively large.They lie far below the fiducial death line on the P-P^(·)diagram.(3)GLEAM-X J162759.5-523504.3 and GPM J1839-10 may be magnetars or white dwarf radio pulsars.At present,there are many parameters and uncertainties in both of these possibilities.展开更多
Purpose: To describe the strategy used for large-scale ophthalmological monitoring in the clinical development of the novel anticancer agent gefitinib (“ Iressa” , ZD1839), an epidermal growth factor receptor tyrosi...Purpose: To describe the strategy used for large-scale ophthalmological monitoring in the clinical development of the novel anticancer agent gefitinib (“ Iressa” , ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, which had demonstrated ocular effects in preclinical animal models. Methods: In this extensive clinical trial programme, patients in Phase I and II trials underwent frequent and intensive ophthalmological monitoring at baseline and during the trials. Data were reviewed by an external independent Ophthalmology Advisory Board. Results: Ophthalmological data for 221 patients in Phase I trials of gefitinib and 425 patients in Phase II trials revealed no evidence of any consistent or drug-related ophthalmological toxicity. Interestingly, the baseline data revealed that, in an asymptomatic population, transient ophthalmological events are identified during monitoring. Conclusions: This study reports the methodology and normative data in an ophthalmological screening programme that should prove useful for future studies.展开更多
基金supported by National SKA Program of China(No.2020SKA0120300)the National Natural Science Foundation of China(NSFC,12133004)。
文摘Recently another long period radio pulsar GPM J1839-10 has been reported,similar to GLEAM-X J162759.5-523504.3.Previously,the energy budget and rotational evolution of long period radio pulsars had been considered.This time,the death line and pulse width for neutron star and white dwarf pulsars are investigated.The pulse width is included as the second criterion for neutron star and white dwarf pulsars.It is found that:(1)PSR J0250+5854 and PSR J0901-4046 etc.should be normal radio pulsars.They have narrow pulse width and they lie near the radio emission death line.(2)The two long period radio pulsars GLEAM-X J162759.5-523504.3 and GPM J1839-10 are unlikely to be normal radio pulsars.Their possible pulse width is relatively large.They lie far below the fiducial death line on the P-P^(·)diagram.(3)GLEAM-X J162759.5-523504.3 and GPM J1839-10 may be magnetars or white dwarf radio pulsars.At present,there are many parameters and uncertainties in both of these possibilities.
文摘Purpose: To describe the strategy used for large-scale ophthalmological monitoring in the clinical development of the novel anticancer agent gefitinib (“ Iressa” , ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, which had demonstrated ocular effects in preclinical animal models. Methods: In this extensive clinical trial programme, patients in Phase I and II trials underwent frequent and intensive ophthalmological monitoring at baseline and during the trials. Data were reviewed by an external independent Ophthalmology Advisory Board. Results: Ophthalmological data for 221 patients in Phase I trials of gefitinib and 425 patients in Phase II trials revealed no evidence of any consistent or drug-related ophthalmological toxicity. Interestingly, the baseline data revealed that, in an asymptomatic population, transient ophthalmological events are identified during monitoring. Conclusions: This study reports the methodology and normative data in an ophthalmological screening programme that should prove useful for future studies.
